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RESEARCH ARTICLE Open Access
Systematic review and meta-analysis: influence of
smoking cessation on incidence of pneumonia in
HIV
Preeti De1, Amanda Farley1, Nicola Lindson1 and Paul Aveyard1,2*
Abstract
Background: Smoking is common in people infected with HIV but cessation support is not a routine part of
clinical care. The aim was to assess whether smoking is a risk factor for pneumonia in people with HIV and
whether smoking cessation ameliorates excess risk.
Methods: We performed MEDLINE and Embase database searches and included cohort or case-control studies
conducted in adult patients infected with HIV extracting a hazard ratio (HR) or odds ratio (OR) that compared the
incidence of bacterial pneumonia or pneumonia caused by Pneumocystis jiroveci (PCP) between two smoking
categories. Studies were appraised for quality and combined using inverse variance meta-analysis.
Results: Fourteen cohort and case-control studies were included. Assessment of outcome was good, but
assessment of exposure status was poor. Current smokers were at higher risk of bacterial pneumonia than former
smokers: HR 1.37 (95% confidence interval (CI): 1.06, 1.78). There was no evidence that former smokers were at
higher risk than never smokers: HR 1.24 (95%CI: 0.96, 1.60). Current smokers were at higher risk of bacterial
pneumonia than current non-smokers: HR of 1.73 (95%CI: 1.44, 2.06). There was no evidence that smoking
increased the incidence of PCP. The HR for current versus non-smokers was 0.94 (95%CI: 0.79, 1.12), but from case-
control studies the OR was 1.76 (95%CI: 1.25, 2.48) with heterogeneity. Confined to higher quality studies, the OR
was 0.97 (95%CI: 0.81, 1.16). Residual confounding is possible, but available data suggest this is not an adequate
explanation.
Conclusions: Smoking is a risk factor for bacterial pneumonia but not PCP and smoking cessation reduces this risk.
See related article: http://www.biomedcentral.com/1741-7015/11/16
Keywords: HIV, meta-analysis, pneumonia, smoking, smoking cessation
Background
Life expectancy in patients with HIV has improved dra-
matically in the era of highly active antiretroviral treat-
ments (HAART), which can prevent the decline in CD4
lymphocyte count and AIDS related morbidity and mor-
tality [1]. However, persons with HIV still face substan-
tially increased health risks compared with the general
population. Another threat to health is that the preva-
lence of cigarette smoking is high amongst people with
HIV at around 50% to 70% [2]. Given that many people
smoke due to nicotine dependence rather than a desire
to smoke and that highly cost-effective treatments for
nicotine dependence are available [3], offering smoking
cessation treatment to patients with HIV could be an
important component of routine clinical care. Currently,
smoking cessation support is not routine [2]. The case
for offering cessation treatment as part of HIV care
rests upon evidence that smoking cessation leads to
improved outcomes specific to this population.
Smoking is a risk factor for bacterial pneumonia in the
absence of HIV and without evidence of chronic obstruc-
tive pulmonary disease. However, it is unclear whether the
elevated risk due to smoking is ameliorated by smoking
cessation [4,5]. Many people in the general population
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who develop pneumonia do so without pre-existing condi-
tions and therefore do not receive regular medical assess-
ment and treatment. However, people with HIV undergo
regular review with the prime aim of preventing opportu-
nistic infection. Pneumonia is an important cause of mor-
bidity and mortality in patients with HIV, and is one of
the most frequent AIDS defining illnesses [6]. If smoking
constitutes a risk factor for pneumonia among patients
with HIV and if smoking cessation ameliorates that risk,
then active management of smoking in people with HIV is
supported. The best evidence of causality that smoking
cessation ameliorates risk would come from randomized
trials of smoking cessation support versus usual care
where the outcomes included incidence of pneumonia.
We identified no such trials. We therefore conducted a
systematic review and meta-analysis of cohort and case-
control studies to assess whether smoking cessation
reduces the incidence of both bacterial pneumonia and
Pneumocystis jiroveci pneumonia (PCP) in patients with
HIV infection, and looked for evidence of a dose-response
relationship to support causality. Furthermore, we exam-
ined whether there was evidence that any risk from smok-
ing or benefit from cessation was modified by the use of
HAART or by CD4 count.
Methods
Eligibility criteria
We included cohort or case-control studies conducted in
adult patients infected with HIV virus. The studies had to
have sufficient information to extract a hazard ratio (HR)
or odds ratio (OR) with 95% confidence intervals (CI)
that compared the risk of bacterial pneumonia or PCP
incidence between two smoking exposure categories.
(HRs require studies to have conducted follow-up and
thus are available only from cohort studies. Case-control
studies can calculate ORs, which approximate the HR
when the event in question is relatively uncommon.)
Data sources and searches
We searched MEDLINE (1950 to January 2010) and
Embase (1947 to January 2010) using a combination of
text word and exploded medical subject headings terms
related to smoking, HIV and pneumonia using the Ovid
interface (Appendix 1 in Additional file 1). Two authors
independently searched through the titles and abstracts to
identify relevant papers for inclusion, with differences
resolved through discussion. We also searched the refer-
ence lists and conducted a citation search of included stu-
dies. Many studies we included were not concerned with
the association between smoking status and incidence of
pneumonia but presented these data incidentally, for
example as part of a multivariable adjustment for the
exposure of interest. We therefore searched the full texts
of all studies with relevant outcomes even if there was no
mention of smoking in the title or abstract.
Data extraction and quality assessment
Two reviewers independently extracted data and resolved
disagreements by recourse to the papers. We extracted
data on demographic and clinical characteristics of the
population (age, gender, use of HAART, CD4+ count)
and on the methods of assessing exposure and outcome
measures. We assessed whether the effect estimate was
adjusted for the effects of potential confounders: use of
intravenous street drugs, alcohol consumption, socio-
economic status (such as educational attainment,
income), CD4 count, viral load, and use of HAART. Each
of these factors is associated with the incidence of pneu-
monia and could plausibly be associated with smoking.
We assessed study quality based on methods outlined
by Altman [7]. We awarded points for assessment of
exposure (smoking), outcome (pneumonia) and whether
potential confounders were either balanced between
exposure groups or controlled for in the analysis
(Appendix 2 in Additional file 1). In many developed
countries, 2% to 3% of smokers stop smoking annually,
therefore ongoing assessment of current smoking status
would be needed to ensure that people defined as cur-
rent smokers were actually exposed. More importantly,
almost all people who have recently stopped relapse to
smoking [8], so we awarded points for baseline assess-
ment that defined former smokers as not having smoked
for at least a year. For the assessment of outcome, our
ideal definition included each of the following: compati-
ble physical symptoms, microbiological confirmation,
and radiographic confirmation. As presented in some
studies, we included either response to antibiotics or
microbiological confirmation as alternative confirmatory
signs. Additional points were awarded if outcome asses-
sors were blinded to exposure status. The maximum
point score was 16 and we classified studies as high
quality when they scored six or more, which was the
median score. We considered and decided against the
use of sensitivity analysis based on key characteristics,
namely the quality of exposure assessment and outcome
assessment. Studies varied little in these two aspects and
so the scoring system mainly reflected differences in the
number of confounders controlled.
Data synthesis and analysis
Risk estimates were extracted as adjusted HRs or ORs
with 95%CIs. If the risk estimates or 95%CIs were not
presented, we calculated them from presented data using
methods described by Parmar et al. [9], or using OpenEpi
software [10]. Where risk estimates were presented as
current or former smokers versus never smokers, we
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compared current smokers with former smokers using
indirect comparison [11].
Adjusted ORs or HRs (where available) were combined
separately from case-control and cohort studies, calculat-
ing summary ORs or HRs respectively using inverse var-
iance fixed effects methods implemented in Review
Manager 5.0.24. We assessed heterogeneity using the I2
statistic and publication bias using funnel plots (shown in
Additional file 1). It is general convention to view I2 values
of less than 25% as showing no appreciable heterogeneity,
between 25% and 50% as moderate, and more than 50% as
substantial heterogeneity. In sensitivity analysis, we con-
fined our analysis to studies defined as high quality. We
combined studies in subgroups where participants did not
use HAART or where HAART was used and assessed
whether use of HAART modified the association between
smoking and pneumonia by the c2 test for heterogeneity.
We assessed whether the association between smoking
and pneumonia incidence was modified by CD4 count.
We used within-study data for this, reporting risk esti-
mates by CD4 strata.
Results
Our search identified 294 studies, of which we obtained 27
full-text articles and 14 studies were included in the review
(Figure 1). Of the 14 observational studies included,
12 examined the effect of smoking status on the incidence
of bacterial pneumonia, with seven (58%) including
Figure 1 Flow diagram.
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patients treated with HAART, and five examined the effect
of smoking status on the incidence of PCP, with two (40%)
including patients treated with HAART (Table 1). There
were five case-control studies and nine cohort studies. In
10 studies the populations were based in the USA, three
were based in Europe, and one in South Africa. The preva-
lence of smoking at cohort inception ranged from 39% to
92% with a median of 60%. Most patients were men
(range 56% to 99%, median 77%) and the average age of
the population was about 40 years (Table 1). Average
length of follow-up in the cohort studies ranged from 1.3
to 10 years (median 4 years), a total of about 62,000 per-
son-years of follow-up in the cohort studies. There were
1,409 participants included in the case-control studies.
Quality assessment
Seven of the 14 studies were not primarily concerned with
the association between smoking and the incidence of
pneumonia, and details of the definition of smoking expo-
sure were scant [12-18]. Even in studies focused on smok-
ing, the definitions of smoking exposure given were
suboptimal and studies lost quality points as a conse-
quence [19-25]. No studies dealt with the fact that former
smokers might relapse while current smokers might
become former smokers. Most studies met the quality cri-
teria for outcome assessment. Eight of the 12 estimates for
bacterial pneumonia risk were adjusted for some prede-
fined confounders [12,14-16,19,21,23,25], with individual
studies adjusting for between three and seven confounders
(median four). Four of the five studies on PCP adjusted for
confounding, range one to four, median 2/3 [19,22,24,25].
We classified six studies scoring six and above as high
quality, of which five had outcomes of bacterial pneumo-
nia [12,14-16,23] and one of PCP [22] (Table 2).
Association between smoking cessation and incidence of
bacterial pneumonia
One cohort study provided an HR for the difference in
incidence between current and former smokers [19]. We
used indirect methods to calculate HRs for this compari-
son from data in three studies [14,21,23]. In comparison
to former smokers, current smoking was associated with a
37% increased risk in developing bacterial pneumonia (HR
1.37; 95%CI: 1.06, 1.78; P = 0.02) (Figure 2). Effect esti-
mates were similar in all four studies with an I2 value of
0%, with no evidence of difference in the pre- to post-
HAART eras (P = 0.70). After excluding studies of lower
quality, the summary estimate did not change greatly, but
was no longer significant (HR 1.28; 95%CI: 0.93, 1.76).
Former smokers versus never smokers and incidence of
bacterial pneumonia
There was no evidence that former smokers were at
greater risk of bacterial pneumonia than never smokers
(HR 1.24; 95%CI: 0.96, 1.60; P = 0.10; I2 = 22%) (Figure 3),
which remained the case after exclusion of lower quality
studies (HR 1.29; 95%CI: 0.79, 2.10). Subgroup analysis for
treatment era showed some evidence that former smokers
on HAART were at higher relative risk from their past
smoking than those not on HAART although the differ-
ence between groups was not significant (P = 0.07).
Current smokers versus current non-smokers and
incidence of bacterial pneumonia
These results, which give direct evidence on the possible
effect of cessation, were supported by more extensive
indirectly relevant data. We pooled eight cohort studies
where the incidence of pneumonia in current smokers was
compared with a combined group of never and former
smokers at study entry (hereafter referred to as non-smo-
kers for simplicity). This produced a summary HR of 1.73
(95%CI: 1.44, 2.06; P <0.001; I2 = 21%) (Figure 4). Con-
fined to four higher quality cohort studies, the HR was
1.64 (95%CI: 1.28, 2.10; I2 = 30%). There were four case-
control studies comparing risk of pneumonia in current
and non-smokers, which gave a pooled OR of 2.12 (95%
CI: 1.63, 2.75; P <0.001) but with more substantial hetero-
geneity (I2 = 46%) (Figure 5). No case-control studies were
rated high quality. In both these meta-analyses there was
weak evidence that the association between smoking and
bacterial pneumonia was modified by the use of HAART.
For current versus non-smokers, the p value for subgroup
differences for cohort studies was 0.17 (Figure 4) and for
case-control studies it was 0.11 (Figure 5). However the
direction of possible effect modification differed, with par-
ticipants using HAART who smoked being at higher risk
from smoking in cohort studies and at lower risk in case-
control studies.
The association between smoking cessation and PCP
Three of five studies containing data on PCP were
cohort studies [19,20,22]. One study reported data that
allowed us to calculate the risk of PCP for current com-
pared with former smokers [19]. There was no evidence
that the risk differed (relative risk (RR) 0.81; 95%CI:
0.55, 1.20).
The overall pooled estimate for current versus non-
smokers from the three cohort studies gave an HR of
0.94 (95%CI: 0.79, 1.12; P = 0.31; I2 = 15%), and from
the two case-control studies gave an OR of 1.76 (95%CI:
1.25, 2.48; P = 0.001) but with substantial heterogeneity
(I2 = 65%) (Figures 6 and 7). The three cohort studies
were all conducted in the pre-HAART era and the two
case-control studies in the post-HAART era. For the
two higher quality cohort studies, the summary HR was
0.97 (95%CI: 0.81, 1.16) with no heterogeneity (I2 = 0%).
There were no case-control studies with a quality score
six or above.
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Assessing the effect of confounding factors
Four studies reported data on both unadjusted and
adjusted HRs in bacterial pneumonia. Hirschtick et al.
reported that adjustment reduced the HR between current
and never smokers but direct numerical comparisons were
not possible [14]. In Gordin et al., adjustment for con-
founding by intravenous drug use, use of HAART, CD4
count and viral load reduced the HR slightly, from 1.80 to
1.64 (former versus never) and 2.19 to 1.82 (current versus
never) [23]. In Caiaffa et al., adjustment for CD4 count,
age and illicit drug use increased the OR slightly from 2.00
to 2.08 [12]. In Miguez-Burbano et al., adjustment for
CD4 count, viral load and use of HAART changed the OR
from 1.80 to 2.28 [25].
There was only one study that allowed comparison
between unadjusted and adjusted estimates of the risk of
PCP. Miguez-Burbano et al. reported that the OR for cur-
rent versus non-smokers decreased on adjustment from
approximately 16 to 1.56 [24].
Dose-response relationships between smoking and
outcomes
No studies examined the effect of years since cessation
on the incidence of pneumonia or even reported on years
of cessation achieved in former smokers. Conley et al.
reported a significant linear trend for risk of bacterial
pneumonia with heaviness of consumption in current
smokers, but no trend for PCP [20]. Miguez-Burbano
et al. reported a significant dose-response relationship,
with the odds of bacterial pneumonia increasing by 3%
per cigarette per day in a linear trend analysis [25]. Galai
et al. reported no association between number of cigar-
ettes smoked and increasing risk of PCP [22].
Is the association between smoking and bacterial
pneumonia or PCP modified by CD4 count?
Three studies reported data for bacterial pneumonia, but
none allowed a quantitative summary of the effect esti-
mates of smoking on pneumonia by CD4 count category.
Hirschtick et al. reported that a low CD4 count (<200
lymphocytes per microliter) was associated with an
increased relative hazard from current smoking [14],
Miguez-Burbano et al. reported a lower relative hazard
[25], and Burns reported no difference in relative hazard
by CD4 count [19]. Galai et al. reported that CD4 count
did not significantly modify the effect of smoking on inci-
dence of PCP [22].
Discussion
We found strong statistical evidence that, in patients with
HIV, current smoking was associated with an approxi-
mate 70% to 100% increased risk of bacterial pneumonia
Table 1 Characteristics of participants in included studies for bacterial pneumonia and Pneumocystis jiroveci
pneumonia.
Reference Number. of
participants
Men
(%)
Mean/median age
(SD) in years
Smokers (%) Non-smokers (%) Mean/median
CD4+ count
Use of HAART
Bacterial pneumonia
[12] 40 75 Median 30 to 40 NR NR NR Pre HAART era
[21] 867 99 Mean 50 (10) 63% 22% former smokers,15%
never smokers
NR Post-HAART era
[13] 509 100 Median 30 80% 20% non-smokers 177 cells/μL Post-HAART era
[23] 5472 73 Median 43 41% 25% former, 34% never
smokers
>350 cells/μL Post-HAART era
[14] 1130 NR NR NR NR NR Pre-HAART era
[15] 885 0 (all
female)
Mean 36 76% 24% NR Pre and Post
HAART era
[16] 1203 77 Mean 36 66% unknown
orcurrent smokers
34% currently not
smoking
279 cells/μL Post-HAART era
[17] 300 56 Mean 37 (7) 92% 8% non-smokers 327 cells/μL Post-HAART era
[18] 285 NR Mean 34 (8) 55% 45% non-smokers 182 cells/μL Pre-HAART era
Bacterial pneumonia and Pneumocystis jiroveci pneumonia
19] 3221 83 Mean 37 57% 19% former smokers,24%,
never smoker
327 cells/μL Pre-HAART era
[20] 232 100 Median 36 to 38 46% 54% NR Pre-HAART era
[25] 521 58 Mean 42 (9) 63% 12% former smokers,25%
never smokers
172 cells/μL Post-HAART era
Pneumocystis jiroveci pneumonia only
[22] 2499 100 NR 39% 61% >200 cells/μL Pre-HAART era
[24] 54 59 Mean 40 NR NR 257 cells/μL Post-HAART era
HAART: highly active antiretroviral treatments; NA: not applicable; NR: not reported.
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compared with non-smokers, and moderate evidence that
stopping smoking decreased this by about 27%. There
was some evidence that former smokers were at slightly
increased risk compared with never smokers, which was
not significant, however the estimate was insufficiently
precise to exclude a substantial increased risk. There was
no good evidence that the risk of smoking was modified
either by the use of HAART or by CD4 count. There was
mixed evidence that smoking increased the risk of PCP,
but higher quality evidence indicated no substantial
increase in risk of PCP from current smoking. The evi-
dence from all studies was somewhat clouded by poor
definition of exposure status (smoking) and failure to
control for a full range of confounders. However, studies
that reported the effects of adjustment suggested that
adjustment for several confounders had an insubstantial
effect on these estimates.
The strengths of this study relate to the comprehen-
sive search of studies that had relevant outcomes even
though the titles or abstracts included no mention of
smoking. We found seven studies this way that did not
have an investigation of smoking as a risk factor for
pneumonia as their prime aim. It is plausible that sev-
eral cohort studies investigating smoking as a risk factor
failed to find a significant association, and therefore did
not publish data. Incorporating studies where smoking
Table 2 Methodological characteristics of studies.
Author
(year)
Study
design
Exposure assessment Outcome assessment Number of
confounders
controlled
Study
quality
score
Definition of smoking Definition
of non
smoking
Method of
assessingsmoking
status
Definition
ofpneumonia
Blinding
ofassessors
toexposure
status (cohort
studies)
Bacterial pneumonia
[12] Case
control
>1 cig/day Never
smoked
Medical history 2 0 3 7
[21] Cohort NR Former and
never,
otherwise
undefined
Questionnaire or
clinical notes
1 0 4 5
[13] Nested
case-
control
NR NR NR 2 1 0 3
[23] Cohort NR NR Interview 2 1 4 7
[14] Cohort NR Never
smokers
<100
cigarettes in
lifetime
NR 2 0 4 6
[15] Cohort NR Not current
smokers
NR 2 0 7 9
[16] Cohort NR NR Questionnaire 2 0 4 6
[17] Cohort NR NR Questionnaire 2 0 0 2
[18] Case
control
>6 cigs/day NR NR 2 0 0 3
Bacterial pneumonia and Pneumocystis jiroveci pneumonia
[19] Cohort NR Self-defined Clinical notes 0 0 4 4
[20] Cohort Cigarettes/day in multiple
categories
NR Questionnaire 1 0 0 2
[25] Case
control
NR NR Questionnaire 2 0 3 5
Pneumocystis jiroveci pneumonia only
[22] Cohort Defined according to daily
cigarette consumption and
change in smoking status
over time
Not currently
smoking
Questionnaire 2 0 2 6
[24] Case
control
Current tobacco use Current non-
smoking
Questionnaire and
clinical notes
2 0 1 4
NR: not reported.
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Study or Subgroup
1.1.1 Pre- HAART
Burns 1996
Hirschtick 1995
Subtotal (95% CI)
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.24 (P = 0.02)
1.1.2 Post - HAART
Crothers 2005
Gordin 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 0.19, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI)
Heterogeneity: Chi² = 0.35, df = 3 (P = 0.95); I² = 0%
Test for overall effect: Z = 2.31 (P = 0.02)
Test for subgroup differences: Chi² = 0.15, df = 1 (P = 0.70), I² = 0%
log[Risk Ratio]
0.33
0.36
0.38
0.1
SE
0.17
0.32
0.5
0.39
Weight
63.0%
17.8%
80.8%
7.3%
12.0%
19.2%
100.0%
IV, Fixed, 95% CI
1.39 [1.00, 1.94]
1.43 [0.77, 2.68]
1.40 [1.04, 1.88]
1.46 [0.55, 3.90]
1.11 [0.51, 2.37]
1.23 [0.67, 2.24]
1.37 [1.05, 1.78]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.5 0.7 1 1.5 2
Former higher risk Current higher risk
Figure 2 Comparison of risk of bacterial pneumonia between HIV seropositive current smokers and former smokers.
Study or Subgroup
2.1.1 Pre-HAART
Burns 1996
Hirschtick 1995
Subtotal (95% CI)
Heterogeneity: Chi² = 0.39, df = 1 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.28 (P = 0.78)
2.1.2 Post- HAART
Crothers 2005
Gordin 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 0.13, df = 1 (P = 0.72); I² = 0%
Test for overall effect: Z = 2.44 (P = 0.01)
Total (95% CI)
Heterogeneity: Chi² = 3.84, df = 3 (P = 0.28); I² = 22%
Test for overall effect: Z = 1.65 (P = 0.10)
Test for subgroup differences: Chi² = 3.32, df = 1 (P = 0.07), I² = 69.9%
log[Risk Ratio]
0.12
-0.09
0.66
0.49
SE
0.2
0.27
0.38
0.28
Weight
42.8%
23.5%
66.3%
11.9%
21.8%
33.7%
100.0%
IV, Fixed, 95% CI
1.13 [0.76, 1.67]
0.91 [0.54, 1.55]
1.05 [0.76, 1.43]
1.93 [0.92, 4.07]
1.63 [0.94, 2.83]
1.73 [1.11, 2.70]
1.24 [0.96, 1.60]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.5 0.7 1 1.5 2
Never higher risk Former higher risk
Figure 3 Risk of bacterial pneumonia in former versus never smokers (cohort studies).
De et al. BMC Medicine 2013, 11:15
http://www.biomedcentral.com/1741-7015/11/15
Page 7 of 12
Study or Subgroup
4.1.1 Pre- HAART
Burns 1996
Conley 1996
Hirschtick 1995
Kohli 2006
Subtotal (95% CI)
Heterogeneity: Chi² = 4.41, df = 3 (P = 0.22); I² = 32%
Test for overall effect: Z = 4.56 (P < 0.00001)
4.1.2 Post- HAART
Crothers 2005
Gordin 2008
Le Moing 2006
Lopez- Palomo 2004
Subtotal (95% CI)
Heterogeneity: Chi² = 2.60, df = 3 (P = 0.46); I² = 0%
Test for overall effect: Z = 4.12 (P < 0.0001)
Total (95% CI)
Heterogeneity: Chi² = 8.85, df = 7 (P = 0.26); I² = 21%
Test for overall effect: Z = 6.00 (P < 0.00001)
Test for subgroup differences: Chi² = 1.85, df = 1 (P = 0.17), I² = 45.8%
log[Risk Ratio]
0.45
0.96
0.26
0.75
1.04
0.6
1.24
0.13
SE
0.16
0.35
0.18
0.27
0.33
0.26
0.6
0.68
Weight
32.4%
6.8%
25.6%
11.4%
76.0%
7.6%
12.3%
2.3%
1.8%
24.0%
100.0%
IV, Fixed, 95% CI
1.57 [1.15, 2.15]
2.61 [1.32, 5.19]
1.30 [0.91, 1.85]
2.12 [1.25, 3.59]
1.61 [1.31, 1.98]
2.83 [1.48, 5.40]
1.82 [1.09, 3.03]
3.46 [1.07, 11.20]
1.14 [0.30, 4.32]
2.15 [1.49, 3.10]
1.73 [1.44, 2.06]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
non smoker higher risk Current higher risk
Figure 4 Risk of bacterial pneumonia in current versus non-smokers (cohort studies).
Study or Subgroup
5.1.1 Pre- HAART
Caiaffa 1994
Tumbarello 1998
Subtotal (95% CI)
Heterogeneity: Chi² = 0.08, df = 1 (P = 0.78); I² = 0%
Test for overall effect: Z = 5.31 (P < 0.00001)
5.1.2 Post- HAART
Charalambous 2003
Miguez- Burbano 2005
Subtotal (95% CI)
Heterogeneity: Chi² = 2.97, df = 1 (P = 0.08); I² = 66%
Test for overall effect: Z = 2.39 (P = 0.02)
Total (95% CI)
Heterogeneity: Chi² = 5.57, df = 3 (P = 0.13); I² = 46%
Test for overall effect: Z = 5.60 (P < 0.00001)
Test for subgroup differences: Chi² = 2.53, df = 1 (P = 0.11), I² = 60.4%
log[Odds Ratio]
0.73
0.94
0.1
0.82
SE
0.74
0.18
0.31
0.28
Weight
3.3%
55.3%
58.5%
18.6%
22.8%
41.5%
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Figure 5 Risk of bacterial pneumonia in current versus non-smokers (case-control studies).
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was not the main focus offers reassurance that the asso-
ciation is not due to publication bias and funnel plots
also suggested no evidence of bias.
There are some limitations with the review and the
data we reviewed. We might have searched a larger
number of databases and we did not search the grey lit-
erature. We included observational data, and there were
inherent limitations. First, the measurement of smoking
was suboptimal. Over time, people who were smokers at
baseline would have stopped smoking, while some ex-
smokers might have relapsed; this will mix exposure
assignment and generally underestimate any true risk of
smoking on pneumonia [26]. Another limitation is that
few studies adjusted for a full range of confounders.
People who smoke are more likely than people who do
not to have other factors associated with an increased
risk of pneumonia, for example, intravenous drug use or
failure to adhere to HAART. Our ability to assess the
importance of this explanation was compromised by
failure to report unadjusted and adjusted estimates, but
those that were presented suggested a small effect of
adjustment and this is unlikely to explain the associa-
tions observed.
Taken together, we believe this systematic review gives
reasonable evidence that the association between smok-
ing and bacterial pneumonia is causal in HIV patients.
There are no strong reasons to doubt the validity of the
association and there was a dose-response relationship
between smoking and risk of pneumonia. There are sup-
porting data that suggest biologically plausible mechan-
isms, such as reduced local defenses in the lung.
Smokers with HIV have lower concentrations of CD4
and CD8 lymphocytes in lung tissue and lower concen-
trations of cytokines IL-1b and TNF-a [27]. There is
also evidence that smoking reduces the phagocytic func-
tion of alveolar macrophages in individuals infected with
Study or Subgroup
3.3.1 Pre HAART
Burns 1996
Conley 1996
Galai 1997
Subtotal (95% CI)
Heterogeneity: Chi² = 2.34, df = 2 (P = 0.31); I² = 15%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Chi² = 2.34, df = 2 (P = 0.31); I² = 15%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
log[Risk Ratio]
-0.11
-0.51
0.03
SE
0.14
0.35
0.12
Weight
39.7%
6.3%
54.0%
100.0%
100.0%
IV, Fixed, 95% CI
0.90 [0.68, 1.18]
0.60 [0.30, 1.19]
1.03 [0.81, 1.30]
0.94 [0.79, 1.12]
0.94 [0.79, 1.12]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
non smokers higher risk current higher risk
Figure 6 Risk of Pneumocystis jiroveci pneumonia in current smokers compared to non-smokers (cohort studies).
Study or Subgroup
3.6.1 Post HAART
Miguez- Burbano 2003
Miguez- Burbano 2005
Subtotal (95% CI)
Heterogeneity: Chi² = 2.86, df = 1 (P = 0.09); I² = 65%
Test for overall effect: Z = 3.25 (P = 0.001)
Total (95% CI)
Heterogeneity: Chi² = 2.86, df = 1 (P = 0.09); I² = 65%
Test for overall effect: Z = 3.25 (P = 0.001)
Test for subgroup differences: Not applicable
log[Odds Ratio]
0.44
1.25
SE
0.19
0.44
Weight
84.3%
15.7%
100.0%
100.0%
IV, Fixed, 95% CI
1.55 [1.07, 2.25]
3.49 [1.47, 8.27]
1.76 [1.25, 2.48]
1.76 [1.25, 2.48]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
non smokers higher risk current higher risk
Figure 7 Risk of Pneumocystis jiroveci pneumonia in current smokers compared to non-smokers (case-control studies).
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HIV [28]. Another possible explanation is that free radicals
in tobacco smoke increase oxidative stress within cells and
therefore enhance the likelihood of infection [29].
This review produced inconclusive evidence on
whether there is an association between current smok-
ing and risk of PCP in patients with HIV. There was no
evidence of a dose-response relationship and, given the
weight of evidence, we conclude that smoking is not a
risk factor for development of PCP. HAART prevents
the occurrence of PCP and antibiotic prophylaxis against
PCP can be stopped in people with a CD4 count greater
than 100 cells/μL [30]. It is clear then that CD4 count is
critical and this reinforces our conclusion that smoking
is not an important risk factor for this pneumonia.
In this meta-analysis, the relative risk of bacterial pneu-
monia in current smokers compared to non-smokers was
26% higher than the relative risk of current smokers
compared to non-smokers. In western countries, where
nearly all of these studies were completed, most non-
smokers aged around 40 years (the average age of partici-
pants in included studies) are never smokers rather than
former smokers [31]. The risk of former smokers in com-
parison to never smokers was imprecisely estimated and
we could not therefore exclude a continued risk in for-
mer smokers. These data are clouded further by the defi-
nitions of smoking status used in these studies. We
cannot therefore be clear that the risk of pneumonia for
former smokers is the same as never smokers, but it is
clear that it is lower than among current smokers.
To our knowledge, no other systematic reviews have
been published on this topic, but narrative reviews have
addressed it [32-34]. This is the first review to explicitly
compare current smokers with former smokers. All but
one study published data comparing the risk of current
smoking to never smokers, but a person who smokes can-
not become a never smoker. Using indirect comparisons
allowed us to estimate the association that is most clini-
cally relevant. We were, however, unable to estimate how
long the risk of current smoking remains elevated after
stopping before the benefits of cessation are manifest.
There are numerous cohort studies of people with HIV
and they are likely to have recorded data on smoking
repeatedly during the follow-up of the cohorts. It would
therefore be useful for these cohorts to examine the differ-
ence in risk by time since cessation and including these
data would allay concerns that smoking status is likely to
have changed over time. There is evidence that smoking
predisposes to tuberculosis, but rather less data on the
effect of smoking cessation on tuberculosis [35]. Such
associations could also be investigated in these studies.
These results have direct clinical implications. The pre-
valence of smoking was high in these cohorts, much
higher than the population in general, in keeping with the
higher prevalence in gay men and intravenous drug users
[36,37]. Two studies reported incidence rates for bacterial
pneumonia, the weighted mean of which was 7.8 per 100
person-years in smokers [14,15]. This means that 25% of
smokers would develop pneumonia over 10 years due to
their smoking that would have been prevented by smoking
cessation. Of cases of pneumonia in people with HIV, 22%
are due to current smoking if the median prevalence of
smoking in these studies (60%) applies generally. Thus it
seems imperative that physicians caring for people with
HIV become proficient in smoking cessation treatment,
regularly offer treatment, and support their patients to
stop smoking. Brief advice to stop smoking is insufficient.
The large majority of people will fail to stop with advice
alone [38]. Many smokers who are gay or current or for-
mer intravenous drug users want to stop smoking but find
this difficult due to nicotine addiction; effective treatment
programs exist that can ameliorate this [3]. The decision
on whether such programs become routine practice in
HIV medicine depends upon showing that they are cost-
effective in this population. Smoking cessation programs
have been called ‘among the most cost-effective of all
healthcare interventions’ (p7 of [39]) in the general popu-
lation, so it seems likely that they would be similarly cost-
effective in people with HIV. There are several small scale
trials published of treatment for smoking cessation in peo-
ple with HIV [40-43], though there is no reason to ima-
gine that treatment regimens in this subgroup need be
very different from standard smoking cessation treatment.
However, it was outside the scope of this review to exam-
ine evidence of efficacy in supporting cessation or its cost-
effectiveness.
Conclusions
There is reasonable evidence that smoking cessation is
casually associated with a reduced risk of bacterial pneu-
monia but not PCP in people with HIV. Smoking cessa-
tion programs should be incorporated into HIV
treatment programs.
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